Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry




Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, Beitner-Johnson D, Benistan K, Cabrera G, Charrow J, Kantola I, Linhart A, Nicholls K, Niemann M, Scott CR, Sims K, Waldek S, Warnock DG, Strotmann J

PublisherNATURE PUBLISHING GROUP

2013

Genetics in Medicine

GENETICS IN MEDICINE

GENET MED

12

15

12

958

965

8

1098-3600

DOIhttps://doi.org/10.1038/gim.2013.53



Conclusion: Agalsidase-beta treatment for >= 2 years may improve or stabilize left-ventricular mass in men with Fabry disease. Further investigations may determine whether early intervention and stabilization of LVM are correlated with clinical outcomes.



Last updated on 2024-26-11 at 22:55